Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 9, 2007, Pages 1065-1074

  Kaiserová, Helena ^a   Šimůnek, Tomáš ^a   van der Vijgh, Wim J F ^b,c   Bast, Aalt ^b   Kvasničková, Eva ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anthracyclines; Cardioprotection; Doxorubicinol; Hydroxyl radical scavenging; Iron chelator; Lipid peroxidation

Indexed keywords

7 MONOHYDROXYETHYLRUTOSIDE; CALCEIN; CARBONYL REDUCTASE; DOXORUBICIN; FLAVONOID; HYDROXYL RADICAL; QUERCETIN; QUERCITRIN; SCAVENGER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY TEST; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON CHELATION; LIPID PEROXIDATION; MALE; MYOBLAST; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

ADOLESCENT; ADULT; ALCOHOL OXIDOREDUCTASES; ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CARDIOTONIC AGENTS; CELLS, CULTURED; DOXORUBICIN; FEMALE; FLAVONOIDS; HEART; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RATS; RATS, WISTAR;

RATTUS;

EID: 34548179685     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2007.05.002     Document Type: Article

References (46)

1. Jones R.L., Swanton C., and Ewer M.S. Anthracycline cardiotoxicity. Expert Opin. Drug. Saf. 5 (2006) 791-809
2. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
3. Hrdina R., Geršl V., Klimtová I., Šimůnek T., Macháčková J., and Adamcová M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove) 43 (2000) 75-82
4. Havsteen B.H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96 (2002) 67-202
5. van Acker S.A.B.E., Kramer K., Grimbergen J.A., van den Berg D.J., van der Vijgh W.J.F., and Bast A. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity. Br. J. Pharmacol. 115 (1995) 1260-1264
6. van Acker F.A.A., Hulshof J.W., Haenen G.R.M.M., Menge W.M., Vijgh v.d.W.J.F., and Bast A. New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Radic. Biol. Med. 31 (2001) 31-37
7. Psotová J., Chlopčíková Š., Miketová P., Hrbáč J., and Šimánek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes: Part III. Apigenin, baicalelin, kaempherol, luteolin and quercetin. Phytother. Res. 18 (2004) 516-521
8. Boucek Jr. R.J., Olson R.D., Brenner D.E., Ogunbunmi E.M., Inui M., and Fleishner S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J. Biol. Chem. 262 (1987) 15851-15856
9. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4 (1990) 3076-3086
10. Forrest G.L., Gonzalez B., Tseng W., Li X., and Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 60 (2000) 5158-5164
11. Olson L.E., Bedja D., Alvey S.J., Cardounel A.J., Gabrielson K.L., and Reeves R.H. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 63 (2003) 6602-6606
12. Kaiserová H., and Kvasničková E. Inhibition study of rabbit liver cytosolic reductases involved in daunorubicin toxication. J. Enzyme Inhib. Med. Chem. 20 (2005) 477-483
13. Forrest G.L., and Gonzalez B. Carbonyl reductase. Chem. Biol. Interact. 129 (2000) 21-40
14. van Acker S.A.B.E., van den Berg D.J., Tromp M.N., Griffioen D.H., van Bennekom W.P., van der Vijgh W.J.F., and Bast A. Structural aspects of antioxidant activity of flavonoids. Free Radic. Biol. Med. 20 (1996) 331-342
15. Schroeder P.E., and Hasinoff B.B. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother. Pharmacol. 50 (2002) 509-513
16. Štěrba M., Popelová O., Šimůnek T., Mazurová Y., Potáčová A., Adamcová M., Kaiserová H., Poňka P., and Geršl V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J. Pharmacol. Exp. Ther. 319 (2006) 1336-1347
17. Šimůnek T., Klimtová I., Kaplanová J., Štěrba M., Mazurová Y., Adamcová M., Hrdina R., Geršl V., and Poňka P. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol. Res. 51 (2005) 223-231
18. Haenen G.R.M.M., Jansen F.P., and Bast A. The antioxidant properties of five O-(β-hydroxyethyl)-rutosides of the flavonoid mixture Venoruton. Phlebology Suppl. 1 (1993) 10-17
19. van Acker F.A.A., Hageman J.A., Haenen G.R.M.M., van der Vijgh W.J.F., Bast A., and Menge W.M. Synthesis of novel 3,7-substituted-2-(3′,4′-dihydroxyphenyl)flavones with improved antioxidant activity. J. Med. Chem. 43 (2000) 3752-3760
20. Bruynzeel A.M., Mul P.P., Berkhof J., Bast A., Niessen H.W., and van der Vijgh W.J.F. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemother. Pharmacol. 58 (2006) 699-702
21. Vlasblom R., Muller A., Musters R.J., Zuidwijk M.J., van Hardeveld C., Paulus W.J., and Simonides W.S. Contractile arrest reveals calcium-dependent stimulation of SERCA2a mRNA expression in cultured ventricular cardiomyocytes. Cardiovasc. Res. 63 (2004) 537-544
22. Brown R.E., Jarvis K.L., and Hyland K.J. Protein measurement using bicinchoninic acid: elimination of interfering substances. Anal. Biochem. 180 (1989) 136-139
23. Fogli S., Danesi R., Innocenti F., Di Paolo A., Bocci G., Barbara C., and Del Tacca M. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther. Drug. Monit. 21 (1999) 367-375
24. Cabantchik Z.I., Glickstein H., Milgram P., and Breuer W. A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells. Anal. Biochem. 233 (1996) 221-227
25. Šimůnek T., Boer C., Bouwman R.A., Vlasblom R., Versteilen A.M., Štěrba M., Geršl V., Hrdina R., Poňka P., de Lange J.J., Paulus W.J., and Musters R.J. SIH - a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J. Mol. Cell. Cardiol. 39 (2005) 345-354
26. Hasinoff B.B., Patel D., and Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic. Biol. Med. 35 (2003) 1469-1479
27. Halliwell B., Gutteridge J.M., and Aruoma O.I. The deoxyribose method: a simple "test-tube" assay for determination of rate constants for reactions of hydroxyl radicals. Anal. Biochem. 165 (1987) 215-219
28. Scalbert A., Manach C., Morand C., Remesy C., and Jimenez L. Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr. 45 (2005) 287-306
29. van Acker S.A.B.E., Boven E., Kuiper K., van den Berg D.J., Grimbergen J.A., Kramer K., Bast A., and van der Wijgh W.J.F. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin. Cancer. Res. 3 (1997) 1747-1754
30. Grisar J.M., Petty M.A., Bolkenius F.N., Dow J., Wagner J., Wagner E.R., Haegele K.D., and de Jong W. A cardioselective, hydrophilic N,N,N-trimethylethanaminium alpha-tocopherol analogue that reduces myocardial infarct size. J. Med. Chem. 34 (1991) 257-260
31. Kaiserová H., den Hartog G.J.M., Šimůnek T., Schro{double acute}terová L., Kvasničková E., and Bast A. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin. Br. J. Pharmacol. 149 (2006) 920-930
32. Gille L., Kleiter M., Willmann M., and Nohl H. Paramagnetic species in the plasma of dogs with lymphoma prior to and after treatment with doxorubicin. An ESR study. Biochem. Pharmacol. 64 (2002) 1737-1744
33. Gille L., and Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic. Biol. Med. 23 (1997) 775-782
34. Xu X., Persson H.L., and Richardson D.R. Molecular pharmacology of the interaction of anthracyclines with iron. Mol. Pharmacol. 68 (2005) 261-271
35. Wang G.X., Wang Y.X., Zhou X.B., and Korth M. Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur. J. Pharmacol. 423 (2001) 99-107
36. van der Vijgh W.J.F., Maessen P.A., and Pinedo H.M. Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother. Pharmacol. 26 (1990) 9-12
37. Boots A.W., Balk J.M., Bast A., and Haenen G.R.M.M. The reversibility of the glutathionyl-quercetin adduct spreads oxidized quercetin-induced toxicity. Biochem. Biophys. Res. Commun. 338 (2005) 923-929
38. Kwok J.C., and Richardson D.R. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol. Pharmacol. 62 (2002) 888-900
39. Kwok J.C., and Richardson D.R. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol. Pharmacol. 63 (2003) 849-861
40. Kwok J.C., and Richardson D.R. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol. Pharmacol. 65 (2004) 181-195
41. Hasinoff B.B. The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction. J. Inorg. Biochem. 95 (2003) 157-164
42. Mira L., Fernandez M.T., Santos M., Rocha R., Florencio M.H., and Jennings K.R. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Radic. Res. 36 (2002) 1199-1208
43. Laughton M.J., Halliwell B., Evans P.J., and Hoult J.R. Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem. Pharmacol. 38 (1989) 2859-2865
44. Ax W., Soldan M., Koch L., and Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 59 (2000) 293-300
45. Imamura Y., Migita T., Uriu Y., Otagiri M., and Okawara T. Inhibitory effects of flavonoids on rabbit heart carbonyl reductase. J. Biochem. (Tokyo) 127 (2000) 653-658
46. Silvestrini A., Meucci E., Vitali A., Giardina B., and Mordente A. Chalcone inhibition of anthracycline secondary alcohol metabolite formation in rabbit and human heart cytosol. Chem. Res. Toxicol. 19 (2006) 1518-1524